Chronic Spontaneous Urticaria (CSU) Clinical Trials

7 recruiting

Chronic Spontaneous Urticaria (CSU) Trials at a Glance

8 actively recruiting trials for chronic spontaneous urticaria (csu) are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in North Miami Beach, Tianjin, and Guangzhou. Lead sponsors running chronic spontaneous urticaria (csu) studies include Novartis Pharmaceuticals, KU Leuven, and Celltrion HealthCare France.

Browse chronic spontaneous urticaria (csu) trials by phase

Treatments under study

About Chronic Spontaneous Urticaria (CSU) Clinical Trials

Looking for clinical trials for Chronic Spontaneous Urticaria (CSU)? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Chronic Spontaneous Urticaria (CSU) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Chronic Spontaneous Urticaria (CSU) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 2Phase 3

Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria (CSU)
Beijing InnoCare Pharma Tech Co., Ltd.344 enrolled30 locationsNCT07378527
Recruiting
Phase 2

Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines

Chronic Spontaneous Urticaria (CSU)Allergic Diseases
Yuhan Corporation150 enrolled30 locationsNCT07415551
Recruiting
Phase 2

Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)

Chronic Spontaneous Urticaria (CSU)
Keymed Biosciences Co.Ltd48 enrolled1 locationNCT07166211
Recruiting
Phase 2

Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria

Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
Novartis Pharmaceuticals44 enrolled17 locationsNCT06865651
Recruiting
Phase 3

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

Chronic Spontaneous Urticaria (CSU)
Novartis Pharmaceuticals400 enrolled114 locationsNCT06868212
Recruiting

ROLL'YN-OMA: an Observational Study in Patients Treated by Omlyclo®, an Omalizumab Biosimilar

Chronic Spontaneous Urticaria (CSU)Allergic Asthma
Celltrion HealthCare France225 enrolled1 locationNCT07425639
Recruiting

Analysis of the Role of IgE Proteoforms in Health and Disease

AnaphylaxisHealthy ControlMastocytosis+6 more
KU Leuven200 enrolled1 locationNCT07328178
Recruiting

SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)

Chronic Spontaneous Urticaria (CSU)Hidradenitis Suppurativa (HS)Psoriasis (PsO)+2 more
Leiden University Medical Center840 enrolled8 locationsNCT07021495